Literature DB >> 10432043

A retrospective examination of sporozoite- and trophozoite-induced infections with Plasmodium falciparum in patients previously infected with heterologous species of Plasmodium: effect on development of parasitologic and clinical immunity.

W E Collins1, G M Jeffery.   

Abstract

A retrospective examination was made to determine parasitemia and episodes of fever in 97 patients, previously infected with Plasmodium malariae, P. ovale, and/or P. vivax, who were reinfected with P. falciparum for treatment of neurosyphilis, the standard treatment at the time. Data were collected at the National Institutes of Health laboratories in Columbia, South Carolina and Milledgeville, Georgia during the period 1940 to 1963. Results were compared with observations recorded for patients following primary infection with P. falciparum. The mean daily percentage of patients with fever > or = 101 degrees F during the first 20 days of primary infection with P. falciparum was 42.4; the percentage with fever > or = 104 degrees F was 19.9%. Those previously infected with P. ovale, P. vivax, and P. malariae had mean daily percentages of fever > or = 101 degrees F and > or = 104 degrees F of 39.1% and 14.8%, 39.1% and 19.4%, and 28.4%, and 11.3%, respectively. Previous infection with P. ovale or P. vivax had little, if any, effect on subsequent clinical malaria due to P. falciparum, whereas infection with P. malariae resulted in reduced frequencies of fever. A similar comparison was made for parasite counts > or = 1,000/microl and > 10,000/microl. The percentages for 268 patients during the first 20 days of primary infection with P. falciparum parasite counts > or = 1,000/microl and > or = 10,000/microl were 58.2% and 29.9%, respectively. Those previously infected with P. ovale, P. vivax, and P. malariae had mean daily percentages of parasitemia > or = 1,000/microl and > or = 10,000/microl of 58.0% and 24.3%, 57.3% and 31.1%, and 45.9% and 19.0%, respectively. Previous infection with P. malariae resulted in a reduction in the frequency of high-density parasitemia (> or = 10,000/microl) as well as an asexual parasite count > or = 1,000/microl. These results suggest that P. falciparum and P. malariae share common antigens that are able to induce parasitologic and clinical protection when infection with P. falciparum follows that with P. malariae. The results did not suggest that protection to P. falciparum is provided by previous infection with P. ovale or P. vivax.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10432043     DOI: 10.4269/tropmed.1999.61-036

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  27 in total

Review 1.  Why do we need to know more about mixed Plasmodium species infections in humans?

Authors:  Peter A Zimmerman; Rajeev K Mehlotra; Laurin J Kasehagen; James W Kazura
Journal:  Trends Parasitol       Date:  2004-09

2.  Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi.

Authors:  R L Culleton; M Inoue; S E Reece; S Cheesman; R Carter
Journal:  Parasite Immunol       Date:  2011-01       Impact factor: 2.280

Review 3.  Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one?

Authors:  Bruno Douradinha; Maria M Mota; Adrian J F Luty; Robert W Sauerwein
Journal:  Infect Immun       Date:  2007-12-03       Impact factor: 3.441

Review 4.  Approaches to malaria vaccine development using the retrospectroscope.

Authors:  Vanessa Sardá; David C Kaslow; Kim C Williamson
Journal:  Infect Immun       Date:  2009-05-18       Impact factor: 3.441

5.  Characterization and application of multiple genetic markers for Plasmodium malariae.

Authors:  M C Bruce; A Macheso; M R Galinski; J W Barnwell
Journal:  Parasitology       Date:  2006-12-04       Impact factor: 3.234

6.  A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP142 in a Prime/Boost Heterologous Immunization Regimen Partially Protects Aotus Monkeys against Blood-Stage Challenge.

Authors:  Nicanor Obaldia; Michael G Stockelman; William Otero; Jennifer A Cockrill; Harini Ganeshan; Esteban N Abot; Jianfeng Zhang; Keith Limbach; Yupin Charoenvit; Denise L Doolan; De-Chu C Tang; Thomas L Richie
Journal:  Clin Vaccine Immunol       Date:  2017-04-05

Review 7.  The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology.

Authors:  K Artavanis-Tsakonas; J E Tongren; E M Riley
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

8.  Acquired immunity in a holoendemic setting of Plasmodium falciparum and p. Vivax malaria.

Authors:  J Kevin Baird; Robert W Snow
Journal:  Am J Trop Med Hyg       Date:  2007-06       Impact factor: 2.345

Review 9.  The impact of malaria parasitism: from corpuscles to communities.

Authors:  Thomas E Wellems; Karen Hayton; Rick M Fairhurst
Journal:  J Clin Invest       Date:  2009-09       Impact factor: 14.808

Review 10.  Asymptomatic malaria infections: detectability, transmissibility and public health relevance.

Authors:  Teun Bousema; Lucy Okell; Ingrid Felger; Chris Drakeley
Journal:  Nat Rev Microbiol       Date:  2014-10-20       Impact factor: 60.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.